JP Morgan Maintains Overweight on Maze Therapeutics, Lowers Price Target to $51

Benzinga · 1d ago
JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and lowers the price target from $53 to $51.